36 results found.

T-cell Lymphomas, T-cell Leukemia, Sezary Syndrome, Mycosis Fungo Clinical Trial using A-dmDT390-bisFv(UCHT1)

Angimmune LLC - Recruiting 18 years or older.
- A Phase I/II Study of A-dmDT390-bisFv(UCHT1) Fusion Protein in Patients With Surface CD3+ Malignant T Cell Diseases.
A-dmDT390-bisFv(UCHT1)

CD20+, B-cell Lymphomas, Mantle Cell Lymphoma, Non-Mantle Cell Lo Clinical Trial using Everolimus and Rituximab

Sidney Kimmel Comprehensive Cancer Center - Recruiting 18 years or older.
- A Trial of Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in CD20+, B-cell Lymphomas and Hodgkin's Lymphoma.
Everolimus and Rituximab

Lymphoma Clinical Trial using Ofatumumab; Ifosfamide; Etoposide; Mesna; G-CSF; Stem Cell Collection

M.D. Anderson Cancer Center - Recruiting 18 years to 70 years.
- Chemotherapy Plus Ofatumumab Followed by G-CSF for Mobilization of Peripheral Blood Stem Cells in Patients With Non-Hodgkin's Lymphomas.
Ofatumumab; Ifosfamide; Etoposide; Mesna; G-CSF; Stem Cell Collection

Lymphoma, Non-Hodgkin Clinical Trial using Copanlisib (BAY80-6946)

Bayer - Recruiting 18 years or older.
- Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas.
Copanlisib (BAY80-6946)

11q-deleted Relapsed/Refractory Chronic Lymphocytic Leukaemia (CL Clinical Trial using Administration of AZD6738

AstraZeneca - Recruiting 18 years or older.
- A Two-part Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-tumour Activity of Multiple Ascending Doses of AZD6738 in Patients With Relapsed/Refractory B Cell Malignancies With Expansion to Patients With Prospectively Identified 11q-deleted or ATM-deficient, Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL).
Administration of AZD6738

Myelodysplastic Syndrome, Hodgkin's Lymphoma, Non-Hodgkin's Disea Clinical Trial using Cyclophosphamide; rituximab; Methotrexate; Sirolimus; Cyclosporine; Doxorubicin hydrochloride; Etoposide; Fludarabine phosphate; Prednisone; Vincristine sulfate; Cytarabine; Tacrolimus; Alemtuzumab

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 74 years.
- Phase II Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Using 8/8 and 7/8 HLA-matched Unrelated Donors and Utilizing Two Graft-versus-Host Disease Prophylaxis Regimens for the Treatment of Leukemias, Lymphomas, and Pre-malignant Blood Disorders.
Cyclophosphamide; rituximab; Methotrexate; Sirolimus; Cyclosporine; Doxorubicin hydrochloride; Etoposide; Fludarabine phosphate; Prednisone; Vincristine sulfate; Cytarabine; Tacrolimus; Alemtuzumab

Lymphomas, or Solid Tumors Clinical Trial using TRC 102; Temozolomide

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase I Trial of TRC102 (Methoxyamine HCl) in Combination With Temozolomide in Patients With Relapsed Solid Tumors and Lymphomas.
TRC 102; Temozolomide

Neoplasms, or Lymphoma Clinical Trial using LMP 400; LMP 776

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and Lymphomas.
LMP 400; LMP 776

Ewing Sarcoma, Gastrointestinal Tumor, Germ Cell Tumor, Hepatic T Clinical Trial using alemtuzumab; fludarabine; sirolimus; Busulfan; melphalan; stem cells

St. Jude Children's Research Hospital - Recruiting 2 years to 21 years.
- A Phase I Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas.
alemtuzumab; fludarabine; sirolimus; Busulfan; melphalan; stem cells

Advanced Solid Tumors, or Lymphoma Clinical Trial using MLN9708

Millennium Pharmaceuticals, Inc. - Recruiting 18 years or older.
- A Phase 1 Study of [14C]-MLN9708 to Assess Mass Balance, Pharmacokinetics, and Metabolism in Patients With Advanced Solid Tumors or Lymphomas.
MLN9708

Advanced Solid Tumors, or Lymphomas Clinical Trial using Camptothecin-20-O-Propionate Hydrate (CZ48)

New Mexico Cancer Care Alliance - Recruiting 18 years or older.
- Phase I and Pharmacology Study of Camptothecin-20-O-Propionate Hydrate (CZ48) in Patients With Solid Tumors or Lymphoma.
Camptothecin-20-O-Propionate Hydrate (CZ48)

Mediastinal Lymph Node Enlargement, Sarcoidosis, Tuberculosis, or Clinical Trial using EBUS guided transbronchial forceps biopsy (EBUS-TBFB); EBUS guided transbronchial needle aspiration (EBUS-TBNA); large bore (19G) histologic needle biopsy of the mediastinal lymph nodes; Bronchoalveolar lavage (BAL); Endobronchial forceps biopsy

Medical University of Warsaw - Recruiting 18 years to 80 years.
- Diagnostic Accuracy of Different Bronchoscopic Sampling Techniques in Patients With Mediastinal Lymph Node Enlargement Suspected of Sarcoidosis.
EBUS guided transbronchial forceps biopsy (EBUS-TBFB); EBUS guided transbronchial needle aspiration (EBUS-TBNA); large bore (19G) histologic needle biopsy of the mediastinal lymph nodes; Bronchoalveolar lavage (BAL); Endobronchial forceps biopsy

Advanced Solid Tumors, or Lymphoma Clinical Trial using MLN8237

Millennium Pharmaceuticals, Inc. - Recruiting 18 years or older.
- An Open-Label, Phase 1, Two-Way, Cross-Over Study of the Effect of the Food on the Pharmacokinetics of MLN8237 (Alisertib) in Patients With Advanced Solid Tumors or Lymphomas.
MLN8237

Solid Tumors, or Lymphoma Clinical Trial using alisertib; esomeprazole; rifampin

Millennium Pharmaceuticals, Inc. - Recruiting 18 years or older.
- Study of the Effect of Esomeprazole or Rifampin on the Pharmacokinetics of Alisertib and Evaluation of the Effect of Alisertib on the QTc Interval in Patients With Advanced Solid Tumors or Lymphomas.
alisertib; esomeprazole; rifampin

Indolent Non-Hodgkin's Lymphomas Clinical Trial using idelalisib; Rituximab; Placebo

Gilead Sciences - Recruiting 18 years or older.
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas.
idelalisib; Rituximab; Placebo

Indolent Non-Hodgkin's Lymphomas Clinical Trial using Rituximab IV 375mg/m2 every 28 days for 4 cycles; bendamustine 90mg/m2 for 2 consecutive days every 28 days for 4 cycles; idelalisib orally 150mg BID; Placebo orally 150mg BID

Gilead Sciences - Recruiting 18 years or older.
- A Phase 3, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas.
Rituximab IV 375mg/m2 every 28 days for 4 cycles; bendamustine 90mg/m2 for 2 consecutive days every 28 days for 4 cycles; idelalisib orally 150mg BID; Placebo orally 150mg BID

Advanced Solid Tumor, or Lymphomas Clinical Trial using LEE011

Novartis - Recruiting 18 years or older.
- A phase1 Multi-center, Open Label, Dose-escalation Study of Oral LEE011 in Patients With Advanced Solid Tumors or Lymphoma.
LEE011

Aggressive B Cell Non-Hodgkin Lymphomas at High Risk for R-CHOP-2 Clinical Trial using lipegfilgrastim; pegfilgrastim

Teva Pharmaceutical Industries - Recruiting 65 years to 85 years.
- A Randomized, Phase IIIB, Open-label, Two-arm, Multicenter, comparatiVe Study on Efficacy and Safety of Lipegfilgrastim (Lonquex, TEVA) in Comparison to Pegfilgrastim (Neulastar, Amgen) in Elderly Patients With Aggressive B Cell Non-HOdgkin Lymphomas at hIgh Risk for R-CHOP-21-inDuced Neutropenia - AVOID Neutropenia.
lipegfilgrastim; pegfilgrastim

Non-Hodgkin's Lymphoma Clinical Trial using Bendamustine; Ofatumumab; Carboplatin; Etoposide; CT Scan; PET Scan; Stem Cell Transplant (STC)

Thomas Jefferson University - Recruiting 18 years or older.
- Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide for Refractory or Relapsed Aggressive B-cell Lymphomas.
Bendamustine; Ofatumumab; Carboplatin; Etoposide; CT Scan; PET Scan; Stem Cell Transplant (STC)

B-cell Chronic Lymphocytic Leukemia, Cutaneous B-cell Non-Hodgkin Clinical Trial using alisertib; romidepsin; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 1 Trial of MLN8237 Plus Romidepsin for Relapsed/Refractory Aggressive B-Cell and T-Cell Lymphomas.
alisertib; romidepsin; laboratory biomarker analysis

Advanced Solid Tumor, or Lymphoma Clinical Trial using DS-3032

Daiichi Sankyo Inc. - Recruiting 18 years or older.
- A Phase 1 Multiple Ascending Dose Study of DS-3032b, an Oral MDM2 Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas.
DS-3032

Adult Grade III Lymphomatoid Granulomatosis, AIDS-related Diffuse Clinical Trial using doxorubicin hydrochloride; vincristine sulfate; vorinostat; prednisone; rituximab; cyclophosphamide; etoposide; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk-Adapted Chemotherapy With Rituximab in HIV-Related B-cell Non-Hodgkin's Lymphoma.
doxorubicin hydrochloride; vincristine sulfate; vorinostat; prednisone; rituximab; cyclophosphamide; etoposide; laboratory biomarker analysis; pharmacological study

Advanced Solid Malignancies, or Malignant Lymphomas Clinical Trial using Gemcitabine HCl Oral Formulation

InnoPharmax Inc. - Recruiting 20 years or older.
- An Open Label, Phase 1, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Clinical Activity of Gemcitabine Hydrochloride Oral Formulation(D07001-F4) in Patients With Advanced Solid Malignancies and Malignant Lymphomas.
Gemcitabine HCl Oral Formulation

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Clinical Trial using romidepsin; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients With, Lymphomas, Chronic Lymphocytic Leukemia and Select Solid Tumors and Varying Degrees of Liver Dysfunction.
romidepsin; pharmacological study

Lung Cancer,, Mediastinal Tumors,, Lymphomas,, or Sarcoidosis, Clinical Trial using virtual bronchoscopy guided transbronchial needle aspiration; endobronchial ultrasound guided transbronchial needle aspiration

Medical University of Warsaw - Recruiting 18 years or older.
- Development and Evaluation of Clinical Utility of Virtual Bronchoscopy (VB)-Based System for Bronchoscopic Navigation, Mediastinal Mapping and Transbronchial Aspiration of Mediastinal Lesions..
virtual bronchoscopy guided transbronchial needle aspiration; endobronchial ultrasound guided transbronchial needle aspiration

CD-30 Positive Anaplastic Large T-cell Cutaneous Lymphoma, Lympho Clinical Trial using SGN-35

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Phase II Trial of Brentuximab Vedotin (SGN-35) at Dose of 1.8 mg/kg IV Every 3 Weeks in Patients With CD30-positive Lymphoproliferative Disorders (Cutaneous Anaplastic Large T-cell Lymphoma (ALCL), Mycosis Fungoides, and Extensive Lymphomatoid Papulosis (LyP).
SGN-35

Non-Hodgkins Lymphoma (NHL) Patients, With CD19+B Cell Lymphomas Clinical Trial using CART-19

Abramson Cancer Center of the University of Pennsylvania - Recruiting 18 years or older.
- Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas.
CART-19

Hodgkin's Lymphoma, or Non-Hodgkin's Lymphoma Clinical Trial using Busulfan; Fludarabine

West Virginia University - Recruiting 18 years to 70 years.
- Once Daily Intravenous Busulfex as Part of Reduced-toxicity Conditioning for Patients With Relapsed/Refractory Hodgkin's and Non-Hodgkin's Lymphomas Undergoing Allogeneic Hematopoietic Progenitor Cell Transplantation - A Multicenter Phase II Study.
Busulfan; Fludarabine

Diffuse Large B Cell Lymphoma Clinical Trial using E7438

Eisai Inc. - Recruiting 18 years or older.
- An Open-Label, Multicenter, Phase 1/2 Study of E7438 (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas.
E7438

Hodgkin Lymphoma, or Diffuse Large B-Cell Lymphoma Clinical Trial using Cylcophosphamide; Etoposide; Alemtuzumab; Doxorubicin; Prednisone; Filgrastim; Rituximab; Vincristine

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas.
Cylcophosphamide; Etoposide; Alemtuzumab; Doxorubicin; Prednisone; Filgrastim; Rituximab; Vincristine

CD30 Positive Primary Mediastinal Large B-cell Lymphoma, CD30 Pos Clinical Trial using brentuximab vedotin

Abramson Cancer Center of the University of Pennsylvania - Recruiting 18 years or older.
- A Phase I/II Study Of Brentuximab Vedotin In Combination With Multi-Agent Chemotherapy As Front-Line Treatment In Patients With CD30 Positive Primary Mediastinal Large B-Cell, Diffuse Large B-Cell, And Grey Zone Lymphomas.
brentuximab vedotin

Leukemia, Myeloid, Chronic, Lymphomas, Multiple Myeloma, Myelodys Clinical Trial using Donor Lymphocyte Infusion; Induction Chemotherapy + DLI

Masonic Cancer Center, University of Minnesota - Recruiting 1 year to 70 years.
- Use of Cyclophosphamide/Fludarabine to Promote in Vivo Expansion of Donor Lymphocyte Infusions (DLI) to Enhance Efficacy After Allogeneic Transplant.
Donor Lymphocyte Infusion; Induction Chemotherapy + DLI

Lymphoma Clinical Trial using alemtuzumab; cyclophosphamide; doxorubicin hydrochloride; prednisone; vincristine sulfate; flow cytometry; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Alemtuzumab and CHOP Chemotherapy for Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Centre Phase I and II Study.
alemtuzumab; cyclophosphamide; doxorubicin hydrochloride; prednisone; vincristine sulfate; flow cytometry; pharmacological study

Lymphoma, Mantle Cell Lymphoma, Indolent Lymphoma, or SLL Clinical Trial using rituximab; bortezomib; cladribine

University of Arizona - Recruiting 18 years or older.
- A Phase II, Open-Label Study of Bortezomib (Velcade), Cladribine and Rituximab (VCR) in Advanced, Newly Diagnosed and Relapsed/Refractory Mantle Cell and Indolent Lymphomas.
rituximab; bortezomib; cladribine

B-Cell Lymphomas Clinical Trial using Ofatumumab

Grupo Espa¤ol de Linfomas y Transplante Aut¢logo de M‚dula Osea - Recruiting 18 years to 65 years.
- Ofatumumab as Part of the Reduced Intensity Conditioning Regimen (RIC) for Patients With High Risk B Non Hodgkin's Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation.
Ofatumumab

T-Cell Lymphomas, or Chemotherapy Clinical Trial using FAD

Fudan University - Recruiting 18 years to 75 years.
- Phase II Study of Orally Fludarabine, Adriamycin and Dexamethasone (FAD) in Newly Diagnosed PTCL.
FAD